HOUSE-BILL 679: H.R.679 - To nullify the modifications made by the Food and Drug Administration in January 2023 to the risk evaluation and mitigation strategy for the abortion pill mifepristone, and for other purposes.
AI-Powered Summary
HOUSE-BILL 679 aims to nullify the FDA's modifications to the risk evaluation and mitigation strategy for mifepristone, which is primarily used for medical abortions. The legislation addresses major themes of reproductive rights, healthcare access, and the balance of power between Congress and regulatory agencies. Key provisions include the prohibition of any similar risk evaluation strategies by the Department of Health and Human Services, which could significantly limit access to abortion services and impact women's healthcare rights. The implementation of this bill raises constitutional concerns regarding personal autonomy and privacy under the Due Process Clause of the Fourteenth Amendment, as well as potential infringements on individuals' rights to access medical care. The timeline for implementation is not specified, but the immediate implications could affect healthcare providers, patients, and the regulatory landscape surrounding reproductive health services.
Demographic Impact Analysis
Summary
Overall Constitutional Implications
The bill poses serious constitutional implications by potentially infringing on established rights related to reproductive health. It could disproportionately affect various demographic groups, particularly women of reproductive age, minors, and low-income individuals, thereby exacerbating existing inequalities in access to healthcare.
Key Individual Rights Affected
- Right to Privacy
- Equal Protection under the Law
- Due Process
Constitutional Provisions Most Relevant
- Fourteenth Amendment - Equal Protection Clause
- Fourteenth Amendment - Due Process Clause
Potential Constitutional Challenges Or Support
Challenges
- The bill may face legal challenges based on its infringement of the right to privacy concerning reproductive choices.
- It could be argued that the bill violates the Equal Protection Clause by disproportionately impacting women and marginalized communities.
Support
- Proponents may argue that the bill reflects the legislative intent to regulate healthcare practices and restore authority to Congress.
Summary Of How This Bill Pertains To Individuals
HOUSE-BILL 679 directly impacts individuals seeking access to mifepristone, particularly women and adolescents, by potentially limiting their reproductive healthcare options. The bill raises significant constitutional concerns regarding privacy, equal protection, and due process, particularly for those in marginalized communities who may already face barriers to healthcare access.
Constitutional Analysis
This bill has been analyzed for constitutional compliance using AI-powered analysis of constitutional principles and precedents.
Analysis generated using AI-powered review of constitutional principles and legal precedents.
Take Action
Text 50409
💡 How to use:
These links will start a conversation with ResistBot. When prompted, mention H.R. 679 to reference this bill.
Contact Your Representatives
Write to YOUR elected officials about this bill
Rate This Bill
Sign in to save a private rating for this bill and track your civic engagement over time.
Sign In FreePolicy Topics
Timeline
January 23, 2025
Bill Introduced
Current
Referred to Committee
June 12, 2026
Last Updated
Ask the Constitutional AI About This Bill
Sign in free to chat with our constitutional analysis AI about this bill — get plain-English explanations, constitutional concerns, and demographic impact estimates personalized to you.
Sign In Free to Chat